Natural Ventures will utilize its state-of-the-art manufacturing facility to manufacture its Viverian CBD product line
VANCOUVER, British Columbia, April 09, 2019 (GLOBE NEWSWIRE) — Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces it will produce and distribute its all-natural CBD product line Viverian, in Puerto Rico, through its subsidiary Natural Ventures.
Viverian is a hemp-derived CBD product line that promotes healthy living and provides consumers with quick and easy methods of consumption. The product line includes CBD tinctures, as well as capsules that may assist with sleep, relaxation, improved concentration, relief for discomfort, and improved overall health and wellness. These products have been lab tested, are THC free, and made of 100% botanical ingredients.
New regulations from the Puerto Rican Department of Health will allow Natural Venture to utilize its high-quality manufacturing facility. The new regulations allow licensed manufacturing facilities to incorporate hemp derived CBD in to its portfolios as long as the products are entered in to the tracking system and tested through licensed labs in Puerto Rico.
Natural Ventures anticipates Viverian products will be available in dispensaries before April 30th, and will also offer contract manufacturing services for other licensees in Puerto Rico.
“Natural Ventures is a key part of Chemesis’ long term strategy to build a major presence in Latin America, and by launching Viverian, it allows penetration into the Puerto Rican CBD market,” said CEO of Chemesis, Edgar Montero. “Chemesis believes it has an advantage in the Latin American CBD market as it is able to leverage its state-of-the-art facility, its previously announced partnership with First Medical that brings up to 6,000 acres of hemp cultivation, and its all-natural Viverian CBD product catalogue.”
For more information on the products, please visit www.viverian.com
On behalf of the board of directors
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within California, Puerto Rico, and finalizing an acquisition in Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release